Cabozantinib in combination with immunotherapy for advanced kidney cancer

In this video interview, Dr Monty Pal from the City of Hope cancer centre in California, USA, talks about the clinical trials involving cabozantinib in combination with atezolizumab for clear cell and non-clear cell renal cell carcinoma (RCC). Watch the video interview on Practice Update here  

read more

Diagnostic biomarkers for rare subtype of kidney cancer

There are more than 10 different subtypes of renal cell carcinoma (RCC), each with important genetic differences that determine how aggressive they are or their response to treatment. Clear cell RCC is the most common subtype, accounting for 75-80% of cases. A team of scientists at the University of Michigan, USA, have discovered the gene […]

read more

Atezolizumab and bevacizumab for non-clear cell renal cell carcinoma

In this video interview from Practice Update, Dr Brad McGregor from Dana-Faber Cancer Institute in Boston, USA, talks about the results from a phase 2 trial with the combination of atezolizumab plus bevacizumab in patients with metastatic non-clear cell renal cell carcinoma (RCC). The study enrolled 60 patients, 42 of which had non-clear cell RCC […]

read more

Nivolumab for the treatment of metastatic non-clear cell renal cell carcinoma

Nivolumab alone and in combination with ipilimumab is used for the treatment of patients with metastatic renal cell carcinoma (RCC) in the second- and first-line, respectively. However, since patients with non-clear cell RCC are excluded from clinical trials, there is limited data on the effectiveness of nivolumab for the treatment of these patients. In a […]

read more

Axitinib first-line treatment of papillary renal cell carcinoma

The majority of renal cell carcinomas (RCCs) are a subtype called clear cell RCC. Most drugs have been developed to treat this subtype of RCC, leaving people with other metastatic RCC subtypes with an unmet need for an effective treatment in the first-line. Papillary RCC (pRCC) represents 10-15% of renal cell carcinomas, and is not an insignificant subtype. […]

read more

ASCO GU 2020: Overall survival results for savolitinib and durvalumab in papillary kidney cancer

Overall survival results from a study with a combination of savolitinib and durvalumab for papillary renal cell carcinoma (RCC) patients were reported at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium held in San Francisco last weekend. Metastatic papillary RCC has poor outcomes and there is need for new treatments. In this phase 1/2 study (CALYPSO), a […]

read more

First-line treatment of papillary renal cell carcinoma with sunitinib

Papillary renal cell carcinoma (PRCC) is a rare subtype of renal cell carcinoma (RCC), accounting for 10%-15% of all cases of RCC. There are two types of papillary RCC; type 1 and type 2. Currently, there is an unmet need for an effective first-line treatment for metastatic PRCC. A recent phase 2 study, published in […]

read more

Atezolizumab and bevacizumab in patients with advanced non-clear cell renal cell carcinoma

Dr Rana McKay from University of California in San Diego, USA and Dr Monty Pal from the City of Hope Medical Centre in California, USA share in a discussion on the study design and results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal […]

read more

Prognosis of type 1 and type 2 papillary renal cell carcinoma

In a recent analysis of a large database, researchers compared baseline clinical/pathological characteristics and survival outcomes of localised type 1 papillary renal cell carcinoma (pRCC) and type 2 pRCC patients. This study, the largest study of localised pRCC published to date, showed that type 2 pRCC patients were more likely to be diagnosed with higher […]

read more

Deciding on the ideal first-line treatment for rare and advanced kidney cancer

Currently, doctors are unsure which is the best first-line treatment for patients with rare and advanced kidney cancers. During a debate at the 18th International Kidney Cancer Symposium (IKCS), 5 doctors discussed their opinions. During the debate, the use of immunotherapy versus targeted kinase inhibitors (TKI) for the first-line treatment of advanced non-clear cell renal […]

read more
Showing 1 to 10 of 45 results
  TOP